• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.

作者信息

Qiu Bin, Cai Kaican, Chen Chun, Chen Jun, Chen Ke-Neng, Chen Qi-Xun, Cheng Chao, Dai Tian-Yang, Fan Junqiang, Fan Zhaohui, Hu Jian, Hu Wei-Dong, Huang Yun-Chao, Jiang Ge-Ning, Jiang Jie, Jiang Tao, Jiao Wen-Jie, Li He-Cheng, Li Qiang, Liao Yong-De, Liu Hong-Xu, Liu Jun-Feng, Liu Lunxu, Liu Yang, Long Hao, Luo Qing-Quan, Ma Hai-Tao, Mao Nai-Quan, Pan Xiao-Jie, Tan Fengwei, Tan Li-Jie, Tian Hui, Wang Dong, Wang Wen-Xiang, Wei Li, Wu Nan, Wu Qing-Chen, Xiang Jiaqing, Xu Shi-Dong, Yang Lin, Zhang Hao, Zhang Lanjun, Zhang Peng, Zhang Yi, Zhang Zhenfa, Zhu Kunshou, Zhu Yuming, Um Sang-Won, Oh In-Jae, Tomita Yusuke, Watanabe Satoshi, Nakada Takeo, Seki Nobuhiko, Hida Toyoaki, Sasada Shinji, Uchino Junji, Sugimura Haruhiko, Dermime Said, Cappuzzo Federico, Rizzo Stefania, Cho William Chi-Shing, Crucitti Pierfilippo, Longo Filippo, Lee Kye Young, De Ruysscher Dirk, Vanneste Ben G L, Furqan Muhammad, Sieren Jessica C, Yendamuri Sai, Merrell Kenneth W, Molina Julian R, Metro Giulio, Califano Raffaele, Bongiolatti Stefano, Provencio Mariano, Hofman Paul, Gao Shugeng, He Jie

机构信息

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

出版信息

Transl Lung Cancer Res. 2021 Sep;10(9):3713-3736. doi: 10.21037/tlcr-21-634.

DOI:10.21037/tlcr-21-634
PMID:34733623
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8512472/
Abstract
摘要

相似文献

1
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.局部晚期非小细胞肺癌围手术期免疫治疗专家共识
Transl Lung Cancer Res. 2021 Sep;10(9):3713-3736. doi: 10.21037/tlcr-21-634.
2
Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer.局部晚期非小细胞肺癌围手术期免疫治疗专家共识
Transl Lung Cancer Res. 2021 Sep;10(9):3709-3712. doi: 10.21037/tlcr-21-764.
3
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).癌症免疫治疗学会关于免疫治疗非小细胞肺癌（NSCLC）的共识声明。
J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.
4
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial.非小细胞肺癌围手术期免疫治疗专家共识：一篇社论
Transl Lung Cancer Res. 2021 Dec;10(12):4322-4327. doi: 10.21037/tlcr-21-882.
5
[Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].《中国晚期非小细胞肺癌抗血管生成药物专家共识（2020年版）》
Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1063-1077. doi: 10.3760/cma.j.cn112152-20200918-00836.
6
[Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].《中国非小细胞肺癌PD-L1表达检测专家共识》
Zhonghua Zhong Liu Za Zhi. 2020 Jul 23;42(7):513-521. doi: 10.3760/cma.j.cn112152-20200313-00202.
7
Expert consensus for training in perioperative echocardiography in the province of Quebec.魁北克省围手术期超声心动图培训专家共识
Can J Anaesth. 2003 Aug-Sep;50(7):699-706. doi: 10.1007/BF03018713.
8
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.免疫治疗之外的治疗选择：野生型肺腺癌患者的德尔菲共识。
Clin Transl Oncol. 2020 May;22(5):759-771. doi: 10.1007/s12094-019-02191-y. Epub 2019 Jul 31.
9
[Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition)].《盐酸安罗替尼治疗晚期肺癌中国专家共识（2020年版）》
Zhonghua Zhong Liu Za Zhi. 2020 Oct 23;42(10):807-816. doi: 10.3760/cma.j.cn112152-20200721-00669.
10
Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer.非小细胞肺癌的围手术期靶向治疗或免疫治疗
Onco Targets Ther. 2019 Oct 3;12:8151-8159. doi: 10.2147/OTT.S222412. eCollection 2019.

引用本文的文献

1
The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer.非小细胞肺癌肿瘤微环境特异性疗法的现状
Cancers (Basel). 2025 May 22;17(11):1732. doi: 10.3390/cancers17111732.
2
BAG2 Inhibits Cervical Cancer Progression by Modulating Type I Interferon Signaling through Stabilizing STING.BAG2通过稳定STING调节I型干扰素信号传导来抑制宫颈癌进展。
Adv Sci (Weinh). 2025 Aug;12(29):e70005. doi: 10.1002/advs.202414637. Epub 2025 May 14.
3
Pharmacokinetics, mass balance, and metabolism of [C]PLB1004, a selective and irreversible EGFR-TKI in humans.[C]PLB1004（一种选择性不可逆表皮生长因子受体酪氨酸激酶抑制剂）在人体内的药代动力学、质量平衡及代谢情况。
Cancer Chemother Pharmacol. 2025 Jan 7;95(1):19. doi: 10.1007/s00280-024-04744-7.
4
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial.卡瑞利珠单抗联合法米替尼治疗既往治疗过的非小细胞肺癌患者的疗效和安全性：一项单臂II期试验
Ther Adv Med Oncol. 2025 Jan 1;17:17588359241311058. doi: 10.1177/17588359241311058. eCollection 2025.
5
Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.非小细胞肺癌合并慢性阻塞性肺疾病患者的新辅助免疫治疗
J Thorac Dis. 2024 Nov 30;16(11):7546-7560. doi: 10.21037/jtd-24-811. Epub 2024 Nov 8.
6
Mistletoe Extracts during the Oncological Perioperative Period: A Systematic Review and Meta-Analysis of Human Randomized Controlled Trials.肿瘤围手术期槲寄生提取物：一项关于人类随机对照试验的系统评价与荟萃分析
Curr Oncol. 2023 Sep 6;30(9):8196-8219. doi: 10.3390/curroncol30090595.
7
Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications.新型细胞和免疫疗法：毒性及围手术期影响。
Curr Oncol. 2023 Aug 16;30(8):7638-7653. doi: 10.3390/curroncol30080554.
8
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.非小细胞肺癌围手术期免疫治疗的进展与展望
Front Oncol. 2023 Jan 25;13:1011810. doi: 10.3389/fonc.2023.1011810. eCollection 2023.
9
Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer.多模式治疗，包括与局部晚期非小细胞肺癌N2受累类型相关的手术
Cancers (Basel). 2022 Mar 25;14(7):1656. doi: 10.3390/cancers14071656.
10
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial.非小细胞肺癌围手术期免疫治疗专家共识：一篇社论
Transl Lung Cancer Res. 2021 Dec;10(12):4322-4327. doi: 10.21037/tlcr-21-882.

本文引用的文献

1
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.SAKK 16/14：在 IIIA（N2）期非小细胞肺癌患者中，新辅助化疗联合度伐利尤单抗：一项多中心单臂 II 期试验。
J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12.
2
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.替雷利珠单抗联合化疗一线治疗局部晚期或转移性非鳞状 NSCLC（RATIONALE 304）：一项随机、III 期临床试验。
J Thorac Oncol. 2021 Sep;16(9):1512-1522. doi: 10.1016/j.jtho.2021.05.005. Epub 2021 May 23.
3
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.PD-L1表达在pN1非小细胞肺癌中的预后影响：一项回顾性单中心分析
Cancers (Basel). 2021 Apr 23;13(9):2046. doi: 10.3390/cancers13092046.
4
The Value of F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.高水平 PD-L1 表达的晚期 NSCLC 患者中 F-FDG PET/CT 预测对 PD-1 阻断免疫治疗反应的价值。
Clin Lung Cancer. 2021 Sep;22(5):432-440. doi: 10.1016/j.cllc.2021.03.001. Epub 2021 Mar 20.
5
Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.纳武利尤单抗联合伊匹单抗用于转移性非小细胞肺癌的一线治疗。
Expert Rev Anticancer Ther. 2021 Jul;21(7):705-713. doi: 10.1080/14737140.2021.1903322. Epub 2021 Mar 28.
6
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review.免疫检查点抑制剂的皮肤不良事件：文献综述
Dermatol Pract Concept. 2021 Jan 29;11(1):e2021155. doi: 10.5826/dpc.1101a155. eCollection 2021 Jan.
7
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.可切除非小细胞肺癌的新辅助纳武利尤单抗或纳武利尤单抗联合伊匹单抗：Ⅱ期随机 NEOSTAR 试验。
Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18.
8
Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer.新辅助化疗免疫治疗/化疗后行袖式肺叶切除术治疗局部晚期非小细胞肺癌
Transl Lung Cancer Res. 2021 Jan;10(1):143-155. doi: 10.21037/tlcr-20-778.
9
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.非小细胞肺癌新辅助免疫治疗专家共识
Transl Lung Cancer Res. 2020 Dec;9(6):2696-2715. doi: 10.21037/tlcr-2020-63.
10
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.卡瑞利珠单抗联合阿帕替尼治疗化疗后晚期非鳞状 NSCLC 患者的疗效和生物标志物分析。
Clin Cancer Res. 2021 Mar 1;27(5):1296-1304. doi: 10.1158/1078-0432.CCR-20-3136. Epub 2020 Dec 15.